199 related articles for article (PubMed ID: 30264382)
1. Effect of Azithromycin on Venetoclax Pharmacokinetics in Healthy Volunteers: Implications for Dosing Venetoclax with P-gp Inhibitors.
Agarwal SK; Tong B; Bueno OF; Menon RM; Salem AH
Adv Ther; 2018 Nov; 35(11):2015-2023. PubMed ID: 30264382
[TBL] [Abstract][Full Text] [Related]
2. Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics.
Freise KJ; Hu B; Salem AH
Eur J Clin Pharmacol; 2018 Apr; 74(4):413-421. PubMed ID: 29302721
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study.
Agarwal SK; Hu B; Chien D; Wong SL; Salem AH
J Clin Pharmacol; 2016 Nov; 56(11):1335-1343. PubMed ID: 26953185
[TBL] [Abstract][Full Text] [Related]
4. Semimechanistic Modeling to Guide Venetoclax Coadministration with Ritonavir and Digoxin.
Alhadab AA; Salem AH; Freise KJ
Clin Transl Sci; 2020 May; 13(3):555-562. PubMed ID: 31961475
[TBL] [Abstract][Full Text] [Related]
5. Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin.
Chiney MS; Menon RM; Bueno OF; Tong B; Salem AH
Xenobiotica; 2018 Sep; 48(9):904-910. PubMed ID: 29027832
[TBL] [Abstract][Full Text] [Related]
6. Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma.
Agarwal SK; Salem AH; Danilov AV; Hu B; Puvvada S; Gutierrez M; Chien D; Lewis LD; Wong SL
Br J Clin Pharmacol; 2017 Apr; 83(4):846-854. PubMed ID: 27859472
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma.
Salem AH; Agarwal SK; Dunbar M; Enschede SL; Humerickhouse RA; Wong SL
J Clin Pharmacol; 2017 Apr; 57(4):484-492. PubMed ID: 27558232
[TBL] [Abstract][Full Text] [Related]
8. Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments.
Agarwal SK; DiNardo CD; Potluri J; Dunbar M; Kantarjian HM; Humerickhouse RA; Wong SL; Menon RM; Konopleva MY; Salem AH
Clin Ther; 2017 Feb; 39(2):359-367. PubMed ID: 28161120
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Subjects with Hepatic Impairment.
Salem AH; Dave N; Marbury T; Hu B; Miles D; Agarwal SK; Bueno OF; Menon RM
Clin Pharmacokinet; 2019 Aug; 58(8):1091-1100. PubMed ID: 30949874
[TBL] [Abstract][Full Text] [Related]
10. Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model.
Freise KJ; Shebley M; Salem AH
J Clin Pharmacol; 2017 Jun; 57(6):796-804. PubMed ID: 28052338
[TBL] [Abstract][Full Text] [Related]
11. Model-Informed Dosing of Venetoclax in Healthy Subjects: An Exposure-Response Analysis.
Dave N; Gopalakrishnan S; Mensing S; Salem AH
Clin Transl Sci; 2019 Nov; 12(6):625-632. PubMed ID: 31268229
[TBL] [Abstract][Full Text] [Related]
12. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
Roberts AW; Davids MS; Pagel JM; Kahl BS; Puvvada SD; Gerecitano JF; Kipps TJ; Anderson MA; Brown JR; Gressick L; Wong S; Dunbar M; Zhu M; Desai MB; Cerri E; Heitner Enschede S; Humerickhouse RA; Wierda WG; Seymour JF
N Engl J Med; 2016 Jan; 374(4):311-22. PubMed ID: 26639348
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of venetoclax in patients with 17p deletion chronic lymphocytic leukemia.
Salem AH; Dunbar M; Agarwal SK
Anticancer Drugs; 2017 Sep; 28(8):911-914. PubMed ID: 28562380
[TBL] [Abstract][Full Text] [Related]
14. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
15. Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study.
Deng R; Gibiansky L; Lu T; Agarwal P; Ding H; Li X; Kshirsagar S; Lu D; Li C; Girish S; Wang J; Boyer M; Humphrey K; Freise KJ; Salem AH; Seymour JF; Kater AP; Miles D
Clin Pharmacokinet; 2019 Dec; 58(12):1621-1634. PubMed ID: 31209657
[TBL] [Abstract][Full Text] [Related]
16. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
[TBL] [Abstract][Full Text] [Related]
17. Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis.
Jones AK; Freise KJ; Agarwal SK; Humerickhouse RA; Wong SL; Salem AH
AAPS J; 2016 Sep; 18(5):1192-1202. PubMed ID: 27233802
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Healthy Chinese Subjects.
Cheung TT; Salem AH; Menon RM; Munasinghe WP; Bueno OF; Agarwal SK
Clin Pharmacol Drug Dev; 2018 May; 7(4):435-440. PubMed ID: 29058801
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B-cell lymphoma-2 inhibitor.
Salem AH; Menon RM
Clin Transl Sci; 2024 May; 17(5):e13807. PubMed ID: 38778732
[TBL] [Abstract][Full Text] [Related]
20. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
Stilgenbauer S; Eichhorst B; Schetelig J; Coutre S; Seymour JF; Munir T; Puvvada SD; Wendtner CM; Roberts AW; Jurczak W; Mulligan SP; Böttcher S; Mobasher M; Zhu M; Desai M; Chyla B; Verdugo M; Enschede SH; Cerri E; Humerickhouse R; Gordon G; Hallek M; Wierda WG
Lancet Oncol; 2016 Jun; 17(6):768-778. PubMed ID: 27178240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
